Avanos Medical, Inc. operates as a medical technology company that focuses on delivering medical device solutions to improve patients' quality of life worldwide. It provides a portfolio of products focuses on respiratory and digestive health; pain management solutions; and minimally invasive interventional pain therapies, closed airway suction systems, and enteral feeding tubes. The company also offers Game Read, a product for pain management and rehabilitation of patients recovering from orthopedic surgery or sports-related injuries; GRPro 2.1, a cold and compression therapy system; Med4Elite, a multi-modality therapy unit; ATX Wraps; and various product accessories. In addition, it sells its products under the ON-Q, COOLIEF, MICROCUFF, MIC-KEY, HOMEPUMP, CORTRAK, and GAME READY brand names. The company markets its products directly to hospitals and other healthcare providers, as well as through third-party distribution channels. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.
Industry, Sector and Symbol
Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone844-428-2667
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$652.30 million
Profitability
Miscellaneous
Employees4,700
Next Earnings Date8/6/2019 (Estimated)
OptionableOptionable
Avanos Medical (NYSE:AVNS) Frequently Asked Questions
What is Avanos Medical's stock symbol?
Avanos Medical trades on the New York Stock Exchange (NYSE) under the ticker symbol "AVNS."
How were Avanos Medical's earnings last quarter?
Avanos Medical Inc (NYSE:AVNS) issued its earnings results on Tuesday, May, 7th. The company reported $0.15 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $0.17 by $0.02. The company earned $164.20 million during the quarter, compared to analysts' expectations of $163.72 million. Avanos Medical had a net margin of 2.58% and a return on equity of 4.92%. The firm's quarterly revenue was up 5.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.76 earnings per share. View Avanos Medical's Earnings History.
When is Avanos Medical's next earnings date?
What guidance has Avanos Medical issued on next quarter's earnings?
Avanos Medical issued an update on its FY19 earnings guidance on Tuesday, May, 7th. The company provided EPS guidance of $1.15-1.35 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.25.
What price target have analysts set for AVNS?
4 equities research analysts have issued twelve-month price objectives for Avanos Medical's stock. Their predictions range from $47.00 to $69.00. On average, they expect Avanos Medical's stock price to reach $60.3333 in the next twelve months. This suggests a possible upside of 47.7% from the stock's current price. View Analyst Price Targets for Avanos Medical.
What is the consensus analysts' recommendation for Avanos Medical?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avanos Medical in the last year. There are currently 2 sell ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Avanos Medical.
Has Avanos Medical been receiving favorable news coverage?
News articles about AVNS stock have trended somewhat positive this week, according to InfoTrie. The research firm identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Avanos Medical earned a news impact score of 0.7 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 7.0 out of 10, meaning that recent press coverage is likely to have an effect on the company's share price in the near future.
Who are some of Avanos Medical's key competitors?
Some companies that are related to Avanos Medical include MSA Safety (MSA), Wright Medical Group (WMGI), Inogen (INGN), Wound Management Technologies (WNDM), Establishment Labs (ESTA), RTI Surgical (RTIX), ConforMIS (CFMS), Invacare (IVC), Sientra (SIEN), Lakeland Industries (LAKE), COLLPLANT HOLDI/S (CLGN), Histogenics (HSGX), NanoVibronix (NAOV), Rewalk Robotics (RWLK) and Bionik Laboratories (BNKL).
What other stocks do shareholders of Avanos Medical own?
Who are Avanos Medical's key executives?
Avanos Medical's management team includes the folowing people:
- Mr. Joseph F. Woody, CEO & Director (Age 53)
- Mr. John W. Wesley, Sr. VP of Legal & Gov. Relations (Age 60)
- Mr. John R. Tushar, Pres of Global Franchises (Age 57)
- Mr. Arjun Ranjan Sarker, Sr. VP of International (Age 53)
- Mr. Warren J. MacHan, Sr. VP of Bus. Strategy & Interim CFO (Age 53)
Who are Avanos Medical's major shareholders?
Avanos Medical's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (11.47%), Champlain Investment Partners LLC (5.06%), Dimensional Fund Advisors LP (5.04%), Victory Capital Management Inc. (4.63%), Paradice Investment Management LLC (3.56%) and Wellington Management Group LLP (3.37%). Company insiders that own Avanos Medical stock include John W Wesley, Joseph Fralin Woody and Steven E Voskuil. View Institutional Ownership Trends for Avanos Medical.
Which major investors are selling Avanos Medical stock?
AVNS stock was sold by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Marshall Wace LLP, New York State Common Retirement Fund, Wells Fargo & Company MN, Morgan Stanley, FMR LLC, First Manhattan Co. and SG Americas Securities LLC. View Insider Buying and Selling for Avanos Medical.
Which major investors are buying Avanos Medical stock?
AVNS stock was bought by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Wellington Management Group LLP, Rice Hall James & Associates LLC, Champlain Investment Partners LLC, Paradice Investment Management LLC, Eagle Asset Management Inc., Lazard Asset Management LLC and JPMorgan Chase & Co.. Company insiders that have bought Avanos Medical stock in the last two years include John W Wesley, Joseph Fralin Woody and Steven E Voskuil. View Insider Buying and Selling for Avanos Medical.
How do I buy shares of Avanos Medical?
Shares of AVNS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Avanos Medical's stock price today?
One share of AVNS stock can currently be purchased for approximately $40.86.
How big of a company is Avanos Medical?
Avanos Medical has a market capitalization of $1.94 billion and generates $652.30 million in revenue each year. The company earns $57.50 million in net income (profit) each year or $0.82 on an earnings per share basis. Avanos Medical employs 4,700 workers across the globe.
What is Avanos Medical's official website?
How can I contact Avanos Medical?
Avanos Medical's mailing address is 5405 Windward Parkway Suite 100 South, Alpharetta GA, 30004. The company can be reached via phone at 844-428-2667 or via email at [email protected]
MarketBeat Community Rating for Avanos Medical (NYSE AVNS)
MarketBeat's community ratings are surveys of what our community members think about Avanos Medical and other stocks. Vote "Outperform" if you believe AVNS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVNS will underperform the S&P 500 over the long term. You may vote once every thirty days.
